Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Retatrutide has an elimination half-life of approximately 6 days
In agreement with the profound anti-inflammatory effects of GLP-1RAs, a recent study demonstrated a protective effect of these medications against the development of non-exudative AMD compared with other diabetes and lipid-lowering medications
The $50 copay does not count toward your Part D out-of-pocket maximum (set at $2,100 in 2026 and $2,400 in 2027)
Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet approved by the MHRA or EMA as of 2024
Retatrutide suppresses appetite it doesn't prevent overeating if you're still eating past the satiety signal
US$ 27.77
US$ 29.60
US$ 24.82
